ULTIMOVACS

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. We enable the immune system to fight cancer... Ultimovacs is developing a new type of cancer treatment. We are currently evaluating the safety and efficacy. We have not secured regulatory approval and so we are not able to use the treatment outside of our clinical trial program... Ultimovacs seeks to become a leader in developing novel immunotherapeutic vaccines to treat a broad range of cancers. Ultimovacs' lead product candidate, UV1, is an off-the-shelf peptide-based therapeutic cancer vaccine. UV1 induces specific T cell responses against the universal, shared cancer antigen telomerase, expressed in 85-90% of cancer indications, across all stages of the disease. Telomerase activation is considered one of the "hallmarks of cancer" due to its selective activation and essential role in continuous cell division. UV1 may potentially be used broadly across multiple cancer types, in different stages..

Also known as: Ultimovacs AB, Ultimovacs ASA, Ultimovacs Company

Primary location: Oslo